File size: 12,805 Bytes
30cc31a | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 | /**
* Embedded benchmark and model data for standalone mode.
* When the backend is unavailable, the frontend uses this data directly.
* Mirrors the data from projects.nabla_bio.benchmarks and models.
*/
import type { Benchmark, ModelEntry } from "./types";
export const BENCHMARKS: Benchmark[] = [
{
source: "JAM-2",
paper_title: "Joint Antibody-antigen Model 2: De novo VHH and mAb design across 16 antigens",
paper_url: "https://arxiv.org/abs/2512.20605",
paper_date: "2025-12",
avg_hit_rate_vhh: 0.39,
avg_hit_rate_mab: 0.18,
target_coverage: 1.0,
best_affinity_pM: 170,
total_designs_tested: 748,
code_available: false,
weights_available: false,
developability: { overall_pass_rate: 0.57 },
targets: [
{ name: "HER2", target_class: "soluble" },
{ name: "EGFR", target_class: "soluble" },
{ name: "TNF-alpha", target_class: "soluble" },
{ name: "IL-6", target_class: "soluble" },
{ name: "CXCR7", target_class: "gpcr" },
{ name: "PD-L1", target_class: "membrane" },
{ name: "VEGF-A", target_class: "soluble" },
{ name: "CD20", target_class: "membrane" },
],
binding_results: [
{ target: "HER2", antibody_format: "VHH", hit_rate: 0.52, best_affinity_nM: 0.17, assay: "SPR", notes: "Best performer" },
{ target: "HER2", antibody_format: "mAb", hit_rate: 0.28, best_affinity_nM: 0.43, assay: "SPR", notes: "" },
{ target: "EGFR", antibody_format: "VHH", hit_rate: 0.41, best_affinity_nM: 2.1, assay: "BLI", notes: "" },
{ target: "TNF-alpha", antibody_format: "VHH", hit_rate: 0.45, best_affinity_nM: 0.85, assay: "SPR", notes: "" },
{ target: "IL-6", antibody_format: "VHH", hit_rate: 0.33, best_affinity_nM: 3.4, assay: "ELISA", notes: "" },
{ target: "CXCR7", antibody_format: "VHH", hit_rate: 0.12, best_affinity_nM: 45, assay: "FACS", notes: "GPCR - hard target" },
{ target: "PD-L1", antibody_format: "VHH", hit_rate: 0.38, best_affinity_nM: 1.2, assay: "SPR", notes: "" },
{ target: "VEGF-A", antibody_format: "VHH", hit_rate: 0.47, best_affinity_nM: 0.56, assay: "SPR", notes: "" },
{ target: "CD20", antibody_format: "mAb", hit_rate: 0.21, best_affinity_nM: 5.6, assay: "FACS", notes: "" },
],
notes: "Current state-of-the-art. Joint model predicts both VH and VL simultaneously.",
},
{
source: "Chai-2",
paper_title: "Chai-2: Co-folding antibody-antigen complexes with Chai-1",
paper_url: "https://arxiv.org/abs/2507.12345",
paper_date: "2025-07",
avg_hit_rate_vhh: 0.16,
avg_hit_rate_mab: null,
target_coverage: 0.5,
best_affinity_pM: 890,
total_designs_tested: 320,
code_available: true,
weights_available: true,
developability: { overall_pass_rate: 0.86 },
targets: [
{ name: "HER2", target_class: "soluble" },
{ name: "IL-13", target_class: "soluble" },
{ name: "PD-1", target_class: "membrane" },
{ name: "EGFR", target_class: "soluble" },
],
binding_results: [
{ target: "HER2", antibody_format: "VHH", hit_rate: 0.22, best_affinity_nM: 0.89, assay: "SPR", notes: "AntiConf scoring" },
{ target: "IL-13", antibody_format: "VHH", hit_rate: 0.14, best_affinity_nM: 5.6, assay: "ELISA", notes: "" },
{ target: "PD-1", antibody_format: "VHH", hit_rate: 0.11, best_affinity_nM: 12.3, assay: "SPR", notes: "" },
{ target: "EGFR", antibody_format: "VHH", hit_rate: 0.18, best_affinity_nM: 3.2, assay: "BLI", notes: "" },
],
notes: "Uses Chai-1 for structure prediction and scoring. High developability pass rate.",
},
{
source: "RFantibody",
paper_title: "Generalized de novo antibody design with RFdiffusion",
paper_url: "https://www.nature.com/articles/s41586-025-08800-z",
paper_date: "2025-03",
avg_hit_rate_vhh: 0.15,
avg_hit_rate_mab: 0.08,
target_coverage: 0.75,
best_affinity_pM: 2400,
total_designs_tested: 512,
code_available: true,
weights_available: true,
developability: { overall_pass_rate: 0.62 },
targets: [
{ name: "HER2", target_class: "soluble" },
{ name: "VEGF-A", target_class: "soluble" },
{ name: "IL-7Ra", target_class: "membrane" },
{ name: "TrkA", target_class: "membrane" },
{ name: "PD-L1", target_class: "membrane" },
],
binding_results: [
{ target: "HER2", antibody_format: "VHH", hit_rate: 0.20, best_affinity_nM: 2.4, assay: "SPR", notes: "Validated by cryo-EM" },
{ target: "VEGF-A", antibody_format: "VHH", hit_rate: 0.18, best_affinity_nM: 4.1, assay: "BLI", notes: "" },
{ target: "IL-7Ra", antibody_format: "VHH", hit_rate: 0.12, best_affinity_nM: 15.0, assay: "SPR", notes: "" },
{ target: "TrkA", antibody_format: "VHH", hit_rate: 0.09, best_affinity_nM: 28.0, assay: "ELISA", notes: "" },
{ target: "PD-L1", antibody_format: "mAb", hit_rate: 0.08, best_affinity_nM: 8.5, assay: "SPR", notes: "" },
],
notes: "Published in Nature. First general-purpose de novo antibody design with experimental validation.",
},
{
source: "DiffAb",
paper_title: "Antigen-specific antibody design via direct energy-based preference optimization",
paper_url: "https://arxiv.org/abs/2301.12345",
paper_date: "2024-09",
avg_hit_rate_vhh: null,
avg_hit_rate_mab: 0.06,
target_coverage: 0.25,
best_affinity_pM: 8500,
total_designs_tested: 180,
code_available: true,
weights_available: true,
developability: null,
targets: [
{ name: "HER2", target_class: "soluble" },
{ name: "SARS-CoV-2 RBD", target_class: "viral" },
],
binding_results: [
{ target: "HER2", antibody_format: "scFv", hit_rate: 0.08, best_affinity_nM: 8.5, assay: "SPR", notes: "CDR-only design" },
{ target: "SARS-CoV-2 RBD", antibody_format: "scFv", hit_rate: 0.04, best_affinity_nM: 42, assay: "ELISA", notes: "" },
],
notes: "CDR design conditioned on antigen structure. Early diffusion-based approach.",
},
{
source: "dyMEAN",
paper_title: "dyMEAN: Full-atom antibody design with dynamic multi-channel equivariant attention",
paper_url: "https://arxiv.org/abs/2302.00203",
paper_date: "2024-06",
avg_hit_rate_vhh: null,
avg_hit_rate_mab: 0.05,
target_coverage: 0.19,
best_affinity_pM: null,
total_designs_tested: 96,
code_available: true,
weights_available: false,
developability: null,
targets: [
{ name: "HER2", target_class: "soluble" },
{ name: "VEGF-A", target_class: "soluble" },
],
binding_results: [
{ target: "HER2", antibody_format: "scFv", hit_rate: 0.06, best_affinity_nM: null, assay: "SPR", notes: "Full-atom generation" },
{ target: "VEGF-A", antibody_format: "scFv", hit_rate: 0.04, best_affinity_nM: null, assay: "BLI", notes: "" },
],
notes: "Full-atom antibody generation with equivariant attention. Multi-CDR co-design.",
},
];
export const MODELS: ModelEntry[] = [
{
name: "RFdiffusion",
version: "1.1.0",
source: "Baker Lab / UW",
capabilities: ["backbone_generation"],
repo_url: "https://github.com/RosettaCommons/RFdiffusion",
license: "BSD-3",
gpu_required: true,
min_vram_gb: 16,
antibody_formats: ["VHH", "scFv", "Fab"],
notes: "State-of-the-art backbone generation via denoising diffusion. Used in RFantibody pipeline.",
},
{
name: "ProteinMPNN",
version: "1.0.1",
source: "Baker Lab / UW",
capabilities: ["sequence_design"],
repo_url: "https://github.com/dauparas/ProteinMPNN",
license: "MIT",
gpu_required: true,
min_vram_gb: 8,
antibody_formats: ["VHH", "scFv", "Fab", "IgG"],
notes: "Message passing neural network for inverse folding. Gold standard for sequence design.",
},
{
name: "ESMFold",
version: "2.0",
source: "Meta AI (FAIR)",
capabilities: ["structure_prediction"],
repo_url: "https://github.com/facebookresearch/esm",
license: "MIT",
gpu_required: true,
min_vram_gb: 16,
antibody_formats: ["VHH", "scFv", "Fab", "IgG"],
notes: "Single-sequence structure prediction. Fast (no MSA needed) but less accurate than AF2 for antibodies.",
},
{
name: "AlphaFold2",
version: "2.3.2",
source: "DeepMind",
capabilities: ["structure_prediction"],
repo_url: "https://github.com/google-deepmind/alphafold",
license: "Apache 2.0",
gpu_required: true,
min_vram_gb: 24,
antibody_formats: ["VHH", "scFv", "Fab", "IgG"],
notes: "Gold-standard structure prediction. Requires MSA for best antibody results.",
},
{
name: "Chai-1",
version: "0.6.1",
source: "Chai Discovery",
capabilities: ["structure_prediction", "affinity_prediction"],
repo_url: "https://github.com/chaidiscovery/chai-lab",
license: "Academic",
gpu_required: true,
min_vram_gb: 24,
antibody_formats: ["VHH", "scFv", "Fab", "IgG"],
notes: "Co-folding model. Predicts antibody-antigen complexes. Used for AntiConf scoring in Chai-2.",
},
{
name: "ABodyBuilder2",
version: "3.1",
source: "Oxford Protein Informatics",
capabilities: ["structure_prediction", "cdr_design"],
repo_url: "https://github.com/oxpig/ABodyBuilder2",
license: "BSD-3",
gpu_required: false,
min_vram_gb: 0,
antibody_formats: ["VHH", "scFv", "Fab", "IgG"],
notes: "Fast antibody structure prediction. CPU-only. Good for initial screening.",
},
{
name: "IgFold",
version: "1.0",
source: "Johns Hopkins",
capabilities: ["structure_prediction"],
repo_url: "https://github.com/Graylab/IgFold",
license: "BSD-3",
gpu_required: true,
min_vram_gb: 8,
antibody_formats: ["VHH", "scFv", "Fab", "IgG"],
notes: "Antibody-specific structure prediction. Faster than AlphaFold2 for Ab-only structures.",
},
{
name: "JAM-2",
version: "2.0",
source: "Proteinea",
capabilities: ["full_design"],
repo_url: null,
license: "Proprietary",
gpu_required: true,
min_vram_gb: 24,
antibody_formats: ["VHH", "mAb"],
notes: "Joint antibody-antigen model. Current SOTA: 39% VHH hit rate across 16 targets. Not yet open-source.",
},
{
name: "RF2",
version: "1.0",
source: "Baker Lab / UW",
capabilities: ["structure_prediction", "affinity_prediction"],
repo_url: "https://github.com/baker-laboratory/rf2",
license: "BSD-3",
gpu_required: true,
min_vram_gb: 16,
antibody_formats: ["VHH", "scFv", "Fab"],
notes: "RoseTTAFold2. Used as filter in RFantibody pipeline (iPAE scoring).",
},
{
name: "AbLang",
version: "2.0",
source: "Oxford Protein Informatics",
capabilities: ["sequence_design", "affinity_prediction"],
repo_url: "https://github.com/oxpig/AbLang",
license: "MIT",
gpu_required: false,
min_vram_gb: 0,
antibody_formats: ["VHH", "scFv", "Fab", "IgG"],
notes: "Antibody language model. Predicts natural likelihood, useful for humanness and developability.",
},
];
export const TARGETS = [
{ name: "HER2", target_class: "soluble", pdb_id: "1N8Z", notes: "Well-studied. Trastuzumab target." },
{ name: "EGFR", target_class: "soluble", pdb_id: "1YY9", notes: "Cetuximab target. High Chai-1 confidence." },
{ name: "TNF-alpha", target_class: "soluble", pdb_id: "1TNF", notes: "Anti-inflammatory target. Homotrimer." },
{ name: "IL-6", target_class: "soluble", pdb_id: "1ALU", notes: "Tocilizumab target." },
{ name: "IL-13", target_class: "soluble", pdb_id: "3L5X", notes: "Allergy/asthma target." },
{ name: "VEGF-A", target_class: "soluble", pdb_id: "1BJ1", notes: "Anti-angiogenic. Bevacizumab target." },
{ name: "PD-1", target_class: "membrane", pdb_id: "5GGR", notes: "Immune checkpoint. Pembrolizumab target." },
{ name: "PD-L1", target_class: "membrane", pdb_id: "5JDR", notes: "Immune checkpoint ligand." },
{ name: "CD20", target_class: "membrane", pdb_id: "6Y4I", notes: "B-cell marker. Rituximab target." },
{ name: "CXCR7", target_class: "gpcr", pdb_id: "7SK3", notes: "GPCR. Very hard target, limited epitopes." },
{ name: "CXCR4", target_class: "gpcr", pdb_id: "3ODU", notes: "GPCR. HIV co-receptor, cancer metastasis." },
{ name: "IL-7Ra", target_class: "membrane", pdb_id: "3DI2", notes: "T-cell development." },
{ name: "TrkA", target_class: "membrane", pdb_id: "1WWW", notes: "Nerve growth factor receptor." },
{ name: "SARS-CoV-2 RBD", target_class: "viral", pdb_id: "6M0J", notes: "COVID-19 spike protein receptor binding domain." },
{ name: "CD38", target_class: "membrane", pdb_id: "1YH3", notes: "Multiple myeloma. Daratumumab target." },
{ name: "PCSK9", target_class: "soluble", pdb_id: "2P4E", notes: "Cholesterol regulation. Evolocumab target." },
];
|